Uniquely Qualified To Collect Cell & Gene Therapy Source Material 

Apheresis Collection Services

Why Are Apheresis Collections Important?

There has been significant growth in the number of clinical trials for cellular and gene therapies (CGT), with the FDA announcing in January 2019 that it had 800 CGT investigational new drug (IND) applications on file and expects to receive 200 new applications annually beginning in 2020. By 2025, the FDA anticipates approving 10 to 20 new cell and gene therapy products each year, meaning that relatively large numbers of these therapies may reach the commercial market within the next five years.

Apheresis is the critical first step in the development of these cellular therapy products. The challenge of collecting cellular therapy products in greater volume while maintaining product integrity highlights the need for high quality, reliable apheresis services.

What Do Apheresis Collections by Comprehensive Cell Solutions Offer?

New York Blood Center’s Comprehensive Cell Solutions (CCS) apheresis collections can provide a variety of cellular components, including:

  • Stimulated or unstimulated apheresis collections using G-CSF and/or plerixafor:

    • Mononuclear cells (lymphocytes and monocytes)

    • Hematopoietic stem cells

  • Red Blood Cells

  • Platelets

  • Granulocytes

These cellular products may be used for training, bench research, and/or clinical trials.

Why Partner with Comprehensive Cell Solutions for Apheresis Collections?

CCS’s resources, expertise, high customer satisfaction and history as a blood center ensures quality systems which address safety, quality, identity, potency and purity and has made CCS an industry leader in apheresis and cellular therapy. CCS offers expertise in clinical trial design, donor recruitment, apheresis collections, and product manufacturing, storage, distribution. Our expertise in apheresis collections service offers the following benefits:

 

  • Available at CCS locations throughout the United States, or at the client’s site

  • Equipped for both autologous (taken from the same person who will get the transplant) and allogeneic (taken from a donor) collections 

  • Donor recruitment pool throughout the country

  • Leukopaks, mononuclear cells (MNCs) or hematopoietic stem cells (HPC) from stimulated donors are collected under IRB-approved protocol

  • Donors are pre-screened for infectious disease

  • Products can have cell counts provided

  • Expert nursing and medical staff

  • Use of FDA-approved equipment at all CCS locations

  • Human leukocyte antigen (HLA) testing available

  • Fully accredited by FACT and AABB

  • Ability to perform cell processing, cryopreservation and storage

  • Resulting cellular product can be stored and/or shipped as needed, fresh or frozen

Contact Us to Learn More

NYBC’s Comprehensive Cell Solutions has been nationally recognized by organizations such as NMDP as a leader in cellular therapy collections. CCS has been collecting, manufacturing, storing and distributing hematopoietic progenitor cell (HPC) products since 1992 and has maintained continuous accreditation by all applicable bodies.

fill out an inquiry form    or Call us at (212) 570-3021 to learn how we can support your organization. For more on cellular therapy apheresis, click here.